Drawing for ACTIMED THERAPEUTICS

USPTO serial 88049205

ACTIMED THERAPEUTICS

Reviewed by CopyMark Law Group

Reg. 6734037Status 700Registered
Filing date
Status date
Registration date
May 24, 2022
Examiner
CORWIN, KEVIN SCOTT
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with ACTIMED THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

M. Scott Alprin

M. Scott Alprin Alprin Law Offices, P.C.5 Pinehurst Circle, N.W.Washington, DC 20015UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical, medical and therapeutic substances and preparations; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of cancers, and of severe or chronic illnesses and diseases; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of physical function; pharmaceutical, medical and therapeutic substances and preparations for treatment and prevention of muscle wasting; pharmaceutical, medical and therapeutic substances and preparations for treatment and management of patient tolerance of therapies, in particular anticancer therapy; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of cachexia, in particular cancer cachexia; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of the side effects of medical treatments, in particular of cancer treatments; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the lung; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the kidney; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the heart; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the liver; pharmaceutical, medical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the brain; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic heart failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic renal failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic liver failure; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of chronic obstructive pulmonary disease; pharmaceutical, medical and therapeutic substances and preparations for countering adverse effects of neurological-muscular disordersACTIVE—
044Information, advisory and consultancy services relating to medicine and healthcare; medical and surgical diagnosis and treatment services; medical analysis and reporting services relating to the treatment of patients; assessment and monitoring of patients; preparation of data and reports relating to medicine and healthcare; medical testing services relating to the diagnosis and treatment of illnesses, diseases and medical conditions; providing information relating to the management, preparation and dispensing of medications; medical, health, dentistry, veterinary and pharmaceutical services; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of cancers, and of severe or chronic illnesses and diseases; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to physical function and muscle wasting; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to patient tolerance of therapies, in particular anticancer therapy; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of cachexia, in particular cancer cachexia; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of the side effects of medical treatments, in particular of cancer treatments; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the lung; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the kidney; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the heart; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the liver; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the brain; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic heart failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic renal failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic liver failure; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of chronic obstructive pulmonary disease; medical diagnosis, treatment, testing, analysis, reporting, assessment and monitoring services relating to countering adverse effects of neurological-muscular disorders; advisory, information and consultancy services relating to all the aforesaid servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 24, 2022NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
May 24, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 8, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 8, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 16, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 27, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 27, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Jan 27, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 27, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 27, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 16, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 16, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 9, 2021ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 1, 2021GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Oct 1, 2021GNSIINQUIRY TO SUSPENSION E-MAILED—
Oct 1, 2021CNSISUSPENSION INQUIRY WRITTEN—
Sep 24, 2021RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Mar 2, 2021RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Aug 6, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Aug 6, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Aug 6, 2020CNSLSUSPENSION LETTER WRITTEN—
Jul 17, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 17, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 12, 2020ALIEASSIGNED TO LIE—
Jun 30, 2020ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jan 27, 2020GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Jan 27, 2020GNSIINQUIRY TO SUSPENSION E-MAILED—
Jan 27, 2020CNSISUSPENSION INQUIRY WRITTEN—
Jul 2, 2019GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jul 2, 2019GNSLLETTER OF SUSPENSION E-MAILED—
Jul 2, 2019CNSLSUSPENSION LETTER WRITTEN—
May 29, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 28, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 28, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 27, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 27, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 27, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 19, 2018DOCKASSIGNED TO EXAMINER—
Nov 19, 2018DOCKASSIGNED TO EXAMINER—
Nov 8, 2018DOCKASSIGNED TO EXAMINER—
Jul 27, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 26, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance